# Forvisirvat

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Forvisirvat
> Markdown URL: https://mediated.wiki/source/Forvisirvat.md
> Source: https://en.wikipedia.org/wiki/Forvisirvat
> Source revision: 1330075137
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

**Forvisirvat** (INN, USAN; developmental code name **SP-624**) is a [sirtuin-6](/source/Sirtuin_6) (SIRT6) activator which is under development for the treatment of [major depressive disorder](/source/Major_depressive_disorder) and [schizophrenia](/source/Schizophrenia).[1][2][3][4][5] It is taken [by mouth](/source/Oral_administration).[1] As of January 2025, forvisirvat is in [phase 2](/source/Phases_of_clinical_research#Phase_II)/[3](/source/Phases_of_clinical_research#Phase_III) [clinical trials](/source/Clinical_trial) for major depressive disorder and is in [phase 1](/source/Phases_of_clinical_research#Phase_I)/2 clinical trials for schizophrenia.[1][2][4] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.[1][2][5]

## See also

- [List of investigational antidepressants](/source/List_of_investigational_antidepressants)
- [List of investigational antipsychotics](/source/List_of_investigational_antipsychotics)

## References

1. ["SP 624"](https://adisinsight.springer.com/drugs/800059680). *AdisInsight*. 29 August 2024. Retrieved 23 October 2024.

1. ["Delving into the Latest Updates on SP-624 with Synapse"](https://synapse.patsnap.com/drug/5e9cf60c85324e4a8747e839e82af610). *Synapse*. 21 September 2024. Retrieved 23 October 2024.

1. Rigdon G, Prescott Y, Hall J, Abernathy K, Raskin J, Wargin W (2025). "Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy Adults". *Clinical Pharmacology in Drug Development*. **14** (1): 18–25. [doi:10.1002/cpdd.1488](https://doi.org/10.1002/cpdd.1488). [ISSN 2160-763X](https://www.worldcat.org/issn/2160-763X). [PMC 11701958](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11701958). [PMID 39587867](https://pubmed.ncbi.nlm.nih.gov/39587867)

1. Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X (March 2024). "Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead". *Acta Pharmaceutica Sinica. B*. **14** (3): 1009–1029. [doi:10.1016/j.apsb.2023.10.023](https://doi.org/10.1016/j.apsb.2023.10.023). [PMC 10935124](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10935124). [PMID 38486982](https://pubmed.ncbi.nlm.nih.gov/38486982)

1. ["Depression treatment shows 'robust efficacy' in women in phase 2 trial"](https://www.healio.com/news/psychiatry/20221019/depression-treatment-shows-robust-efficacy-in-women-in-phase-2-trial). *Daily Medical News, Free CME and Clinical Guidance*. 19 October 2022. Retrieved 23 October 2024.

---
Adapted from the Wikipedia article [Forvisirvat](https://en.wikipedia.org/wiki/Forvisirvat) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Forvisirvat?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.